KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Liabilities: 2019-2024

Historic Total Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $304.5 million.

  • AbCellera Biologics' Total Liabilities rose 24.54% to $392.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.0 million, marking a year-over-year increase of 24.54%. This contributed to the annual value of $304.5 million for FY2024, which is 9.32% down from last year.
  • Latest data reveals that AbCellera Biologics reported Total Liabilities of $304.5 million as of FY2024, which was down 9.32% from $335.8 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Total Liabilities registered a high of $335.8 million during FY2023, and its lowest value of $175.0 million during FY2020.
  • Moreover, its 3-year median value for Total Liabilities was $307.6 million (2022), whereas its average is $316.0 million.
  • Per our database at Business Quant, AbCellera Biologics' Total Liabilities surged by 1,807.26% in 2020 and then declined by 9.32% in 2024.
  • Yearly analysis of 5 years shows AbCellera Biologics' Total Liabilities stood at $175.0 million in 2020, then spiked by 67.31% to $292.8 million in 2021, then grew by 5.05% to $307.6 million in 2022, then climbed by 9.15% to $335.8 million in 2023, then fell by 9.32% to $304.5 million in 2024.